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Ki67 Reactivity in Nasal and Periocular Squamous Cell Carcinomas
in Cats Treated with Electron Beam Radiation Therapy
Katja Melzer, Franco Guscetti, Carla Rohrer Bley, Andrea Sumova, Malgorzata Roos, and
Barbara Kaser-Hotz
Squamous cell carcinomas of sparsely haired skin are relatively common tumors in cats, and these tumors likely exhibit a rapid
growth rate. Thus, we evaluated response and duration of response in relation to the Ki67 proliferative reactivity in such
tumors. Seventeen cats with confirmed squamous cell carcinomas and treated with an accelerated, hypofractionated electron
beam radiation protocol were included in the study. For all of them histologic grading, Ki67 reactivity, response, and disease-
free interval (DFI) were evaluated. Response to therapy was excellent (94% complete response rate) with a median DFI of
414 days. Only moderate acute and few long-term adverse effects were seen. Cats with tumors with a low Ki67 reactivity had
markedly shorter DFIs than cats with tumors with high Ki67 reactivity. We concluded that an accelerated, hypofractionated
electron beam radiation therapy protocol is well suited for feline squamous cell carcinomas. The protocol appears especially
efficacious in tumors with a high Ki67 reactivity.
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C utaneous squamous cell carcinomas are relativelycommon tumors in cats and believed to be induced
by ultraviolet light. Typical localizations are ears,
eyes, and nose, especially in cats with poorly pig-
mented skin.1 Many different treatment modalities have
been described, such as surgery, radiation therapy,
photodynamic therapy, and intralesional chemothera-
py2–6. All treatment modalities have been shown to be
successful. In contrast to surgery, radiation therapy was
found to be a cosmetically appealing and effective
option.4,6–8
Squamous cell carcinomas are thought to be rapidly
dividing tumors. A potential tumor doubling time of
approximately 5 days was determined by using flow
cytometry and bromodeoxyuridine (BrdU) staining.9
Therefore, an accelerated, hypofractionated electron
beam radiation protocol, similar to a previously estab-
lished proton beam radiation protocol10 was used and
evaluated.
Although BrdU labeling is the most reliable test to
evaluate proliferation in tumors, it requires in vivo
injection of BrdU before tissue sampling and cannot be
performed retrospectively on archival material. A
commonly utilized proliferation index is Ki67 immuno-
histochemistry, which identifies the percentage of Ki67
antigen-expressing tumor cells. The Ki67 antigen is
expressed in proliferating cells during all phases of the
cell cycle (G1, G2, M, and S phase), but is not found in
differentiated, dormant cells in G0. Ki67 methodology
has been established in feline formaline-fixed tissue in
apocrine sweat gland tumors, meningiomas, and mela-
nocytic tumors.11,12
The aim of this retrospective study was to evaluate
the efficacy of an accelerated, hypofractionated electron
beam radiation treatment for feline nasal and periocular
squamous cell carcinomas. In addition, the impact of
proliferative activity of tumor cells on disease-free
interval (DFI) was measured by Ki67 immunohisto-
chemistry.13 We hypothesized that tumors with high
proliferative activity would respond more effectively and
for a longer period of time to accelerated radiation
therapy than would tumors with low proliferative
activity.
Materials and Methods
Cats included in this retrospective study had electron beam
radiation therapy without previous local or medical therapy.
Tumors were histologically confirmed cutaneous nasal or perio-
cular squamous cell carcinomas. Records contained information
about age, signalment, breed, weight, sex, color of the face, and
tumor location for all animals. Data about treatment response and
DFI also were available. The 17 cats included in this study were
treated between June 2000 and July 2004 in the section of
Diagnostic Imaging and Radiation Oncology at the Vetsuisse-
Faculty, University of Zurich, Zurich, Switzerland.
All cats were treated by using a linear acceleratora with a single
field, either applied from laterally or dorsocranially depending on
the location of the tumor. The energy of the electron beam was
chosen depending upon the depth of the tumor and ranged from 5
to 16 MeV. Wet gauze of 2- to 4-mm thickness was used to build up
the radiation dose on the skin surface. Treatment planning was
done manually. One centimeter was added to the target volume of
palpable tumor to decrease risk of underestimating tumor size. A
total dose of 48 Gy was given in 10 fractions of 4.8 Gy on 5
consecutive days. To overcome rapid regrowth, 2 fractions at least
6 hours apart were given per day. Beeswax eye shielding was used if
indicated to protect the cornea.
To decrease the risk for anemia due to frequent propofol
administration, 2 alternating anesthetic protocols were used. Either
a midazolamb and propofolc or a ketamined-valiume combination
was given.
Before therapy, the tumors were staged according to Magne et
al2 (see Table 1). Tumor size and invasiveness were judged by
palpation and histopathology as well as by using visual criteria.
Tumor volume was calculated by the formula p/63 length3 width
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3 depth.14 Mandibular lymph nodes were aspirated and cytolog-
ically evaluated for regional metastasis, and 2 lateral thoracic
radiographs were taken to search for distant metastasis. CBC and
serum biochemistry were performed to evaluate of general health
status.
Two consecutive histologic tumor sections 30 mm apart stained
with hematoxylin and eosin were evaluated and graded by 1
pathologist (FG). A grading system described by Carpenter et al15
for squamous cell carcinoma of the tongue in dogs was used with
slight modifications. Three grades (I, II, and III) were distin-
guished, where higher grades indicate more malignant morphology.
Four characteristics (lack of differentiation, lack of keratinization,
mitotic rate, and nuclear polymorphism) were scored based on the
following scale: 0 5 not observed, 1 5 slight, 2 5 moderate, and 3
5 extensive. All mitotic figures in ten 4003 magnification fields
were counted, and the mitotic score was noted as 0 5 no mitosis, 1
5 ,20, 2 5 20–40, and 3 5 .40 mitotic figures. Tissue invasion
was scored as 0 5 none, 1 5 predominantly noninfiltrative or well-
delineated infiltrating borders, and 2 5 infiltrating borders with
cellular dissociation in small groups of cells or single cells. Scirrous
reaction was scored as 05 none or slight and 1 5 pronounced. For
each tumor, the scores for each characteristic were added and a sum
,8 was assigned grade I, 8–10 grade II, and .10 grade III.
A proliferation score was determined by means of immunohis-
tochemistry for Ki-67 antigen (MIB-1). Serial 4-mm sections were
cut and mounted on slides and dried overnight at 37uC. Antigen
retrieval was performed by microwaving slides for 10 minutes in
citrate buffer at pH 6.0. Immunohistochemical staining was
performed automatically in a DAKO Autostainer using the
ChemMate systemf by following the manufacturer’s instructions.
Briefly, 1 section of each sample was incubated with an antibody
specific for Ki-67 (clone MIB-1, M7240g) for 1 hour at room
temperature and at a dilution of 1 : 100. The secondary biotinylated
antibodies were applied for 10 minutes, the peroxidase blocking
solution for 5 minutes, and the streptavidin peroxidase and the 3-
amino-9-ethyl carbazole (AEC)/H2O2 substrate solution were
applied for 10 minutes each. The slides were rinsed with wash
buffer between steps. Finally, the sections were counterstained with
hemalum. In most samples, normal epidermis with hair follicles
was present adjacent to the tumor tissue and served as a positive
and negative control. Positive control staining was found in some
basal and in hair bulb keratinocytes, whereas no staining was seen
in arrector pili muscles. In addition, a negative control using
phosphate-buffered saline instead of the primary antibody was
performed on another section of each sample (Fig 1).
Six hundred to 800 cells, except in 1 case (300 cells), were
counted in digital images from several randomly chosen regions of
each tumor. The percentage of positive cells was determined by
dividing the number of positive cells by the total number of cells
counted. Score 0 was defined as 0–4% positive cells, score 1 as 5–
19%, score 2 as 20–59%, and score 3 as more than 60% positive
cells.
Response was evaluated at the time of recheck 3 weeks
postradiation. Response was considered as complete when no
tumor was visible and the tissue re-epithelized, as partial when
.50% regression was seen, and as no response when tumor had
regressed ,50% or was growing. DFI was defined as the time from
end of therapy until local, regional, or distant failure. Follow-up
information was gathered by follow-up examinations, phone
conversations, and photographs from owners and referring
veterinarians.
Radiation reactions were graded according to the criteria of the
Veterinary Radiation Therapy Oncology Group.16 Reactions
occurring within the first 3 weeks after radiation were considered
acute. Those observed from 3 months after radiation therapy up to
the time the cat was lost to follow-up or died were considered late
effects. Acute grade 1 toxicities were defined as erythema and
alopecia; grade 2 as erythema, alopecia, and moist patchy
desquamation; and grade 3 toxicity as more confluent moist
desquamation and edema. Late toxicity was defined as grade 1 if
slight alopecia, and grade 2 if slight alopecia and mild fibrosis of
the skin were visible. In grade 3 toxicities, severe fibrosis and
necrosis of tissue were obvious.
Statistical Analysis
The following parameters were evaluated with help of the
StatView statistical analysis soft wareh: age, weight, sex, anatomic
location, tumor volume, laboratory abnormalities, histologic
grade, stage of the tumor, Ki67 reactivity, and acute and late
toxicities; and DFI was evaluated with simple descriptive
statistics17. A Kaplan-Meier description17 was used for DFI. For
statistical analysis, DFI was chosen over survival, because DFI
gives a more precise estimate for tumor control. Some owners keep
cats with squamous cell carcinoma alive for a very long time,
despite massive tumor growth, whereas others decide soon for
euthanasia. The differences in DFI among cats with different scores
of Ki67 were investigated by the log rank test.17 DFI compared to
the Ki67-positive reacting cells, the stage of the tumor, and the
tumor volume was evaluated by Cox regression.17 Pearson
correlation17 was computed between Ki67 and stage, grade, age,
weight, sex, location, and tumor volume. When the assumption of
the bivariate normal distribution was violated, the Spearman rank
correlation17 was computed. It computed between tumor volume
and stage, between stage and anemia, and between Ki67 and grade,
stage, and tumor volume. Mann-Whitney analysis17 was used to
analyze sex versus age, location versus stage, and Ki67 versus
location. Cats were censored from evaluation of DFI for continued
life without recurrence or death before recurrence of tumor. DFI
was evaluated with a Kaplan-Meier survival plot. Significance was
defined as P , .05.
Results
Sixteen of the treated cats were Domestic Shorthairs
and 1 was a Domestic Longhair. Mean and median
ages of the 17 cats were 11.1 and 11.2 years, re-
spectively (range, 8–14 years). Nine were spayed females
and 8 were castrated males. Mean and median weight
was 4.3 kg. Neither breed nor sex predilection was
found.
Anemia was a commonly found laboratory abnor-
mality, with only 3 cats having PCV results within
reference limits. The mean PCV was 30.1%, with a range
from 21 to 42%. Because almost all cats were anemic, no
correlation could be found to DFI. Other abnormalities
encountered included slightly increased aspartate ami-
notransferase and alanine aminotransferase activities (2
cats), neutrophilia (1 cat), increased serum levothyroxine
Table 1. World Health Organization slassification of
feline tumors of epidermal origin, as modified by Magne
et al.2
Tumor Stage Description
T1a ,1.5-cm diameter, noninvasive
T1b ,1.5-cm diameter, invasive
T2a .1.5-cm diameter, noninvasive
T2b .1.5-cm diameter, invasive
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concentration (1 cat), and decreased serum albumin
concentration (1 cat).
Twelve tumors were located on the nose and 5
periocularly. Median tumor volume was 0.29 cm3, with
a range of 0.01–25.4 cm3. Tumors were diagnosed as
stage T2b (6 cats), T1b (5 cats), and T1a and T2a (3 cats
each). Regional lymph nodes of all cats were free of
metastasis. No cat showed evidence of distant metastasis
on the thoracic radiographs. Histologically, most
tumors were grade 3 (11 cats), 7 cats had grade 2
tumors, and only 1 cat was diagnosed as having a grade
1 tumor.
For Ki67 immunoreactivity an average of 660 cells
was evaluated (all but 1 cat [300 cells] had more than 500
cells evaluated). All tumors were positive on Ki67
immunohistochemistry. The range of labeled cells was
between 8.3 and 81.6%. The cat with no response to
radiation therapy had the lowest count of only 8.3%
positively staining cells (Table 2).
All but 1 cat showed complete tumor response. Six
cats had local recurrence with very rapid and aggressive
growth after recurrence. Three (18%) of 17 cats in this
study showed regional or distant metastasis, whereas 2
also had local recurrence at the same time. The other cat
was diagnosed 2 months after radiation with regional
lymph node metastasis and was treated with excision of
the node. No tumor recurrence or further metastasis was
detected in the remaining follow-up time of 1,390 days.
The remaining 10 cats did not show any recurrence or
metastasis and were still alive at the conclusion of the
study.
Most acute radiation reactions (10 cats) were grade 1–
2 toxicities with erythema, alopecia, and some patchy,
moist desquamation. Six cats had grade 2–3 toxicities
with more confluent moist desquamation and some
edema. In 1 cat, grade 1 toxicity was seen with only mild
erythema. Late toxicity was mild to moderate with 13
grade 1 and 4 grade 2 toxicities. Grade 1 toxicity
included alopecia, whereas grade 2 was defined as
alopecia and fibrosis. In 4 cats, owners reported
frequent sneezing episodes in the long-term follow-up
.3 months after therapy (Fig 2). No bone necrosis
could be seen in any of the cats during the follow-up
time. No correlation was found between tumor size or
radiation field and severity of toxicity.
Median DFI was 414 days (range, 21–1,450 days).
One cat with a Ki67 score 5 1 had a DFI of only
21 days. Median DFI for cats with Ki67 score 5 2 was
487 days (9 cats), and with score 5 3 (7 cats) it was
1,129 days. One- and 2-year DFIs were 66 and 40%,
respectively. Higher stage of tumor showed a clear
tendency to correlate with shorter DFI (P 5 .056).
Although only a small number of cats were included in
the study, a significant inverse correlation was found
between Ki67 reactivity and DFI (P 5 .035). No
significant difference was found between Ki67 reactivity
and location of the tumor, tumor volume, stage, or
Table 2. Overview of all treated cats included in the study.
Cat Age
(years) Sex
Tumor
Localiza-
tion
PCV
(%)
Tumor
Volume
(cm3) Stage Grade
% Ki67-
Positive
Cells
Ki67
Score
Acute
Toxicity
(grade)
Late Toxicity
(grade)
DFI
(days)
Survival
(days) Censored
11 fs Nose 36 0.690 2 3 60.6 3 3 1 .1,450 SA No
14 mc Eye 24 25.400 5 3 47.8 2 3 1 120 120 No
8 fs Nose 42 0.094 2 2 36.7 2 2 2 .300 SA No
11 mc Nose 24 1.942 4 2 58.7 2 2 1 .977 SA No
8 fs Eye 26 0.220 2 2 60.6 3 3 1 .987 SA Yes
12 mc Nose 34 0.010 1 2 50.2 2 2 1 .987 SA Yes
12 fs nose 27 0.722 4 2 45.3 2 2 1 .952 SA Yes
14 mc Eye 28 3.140 4 3 8.3 1 2 2 21 LTF No
12 fs eye 29 0.285 3 3 73.0 3 2 1 414 414 No
8.5 mc Nose 35 0.019 2 2 63.8 3 3 0 .623 SA Yes
8.7 fs Nose 24 0.026 1 1 74.9 3 2 1 .567 SA Yes
8 fs Nose 42 0.031 1 2 42.7 2 2 1 98 124 No
11.5 fs Eye 29 0.523 4 3 54.2 2 3 1 88 104 No
9.5 mc Nose 34 0.157 3 3 81.6 3 1 1 .242 SA No
14 mc Nose 21 1.569 3 1 46.3 2 2 2 171 171 No
fs Nose 43 2.510 4 2 52.7 2 2 1 .300 SA Yes
15 mc Nose 35 0.293 2 3 71.0 3 3 2 .494 SA Yes
DFI, disease-free interval; fs, female, spayed; mc, male, castrated; SA, still alive; LTF, lost to follow-up after 40 days.
Fig 1. Score 3 Ki67 immunohistochemistry of a nasal squamous
cell carcinoma.
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grade. Also in the multivariate analysis with stage,
grade, and anatomic location included, Ki67 showed
significance only with DFI. A Kaplan-Meier survival
plot applying Ki67 score is shown in Figure 3.
Discussion
Rapid tumor proliferation influences response to
radiation treatment. Proliferation of surviving tumor
cells between radiation fractions may lead to a decreased
tumor control. A more rapidly administered radiation
protocol will counteract this proliferation. An acceler-
ated protocol implies that the radiation is given over
a shorter time than in conventional treatment. Hypo-
fractionation means that larger doses per fraction are
given to achieve a shorter overall treatment time, but the
risk of delayed toxicity is increased.10
In a previous study,8 an accelerated, hypofractionated
proton radiation therapy regimen was shown to be
efficatious and well tolerated for the treatment of feline
squamous cell carcinomas. DFI of cats in this study was
440 days with a 1-year DFI of 64%. Because of
restricted availability of the cyclotron, therapy had to
be given within 1 week. Although proton radiation
treatment is a modality that is highly conformed to the
tumor target, it is unfortunately expensive and not
readily available. Therefore, a similar radiation treat-
ment protocol was originally established that used
electron beam radiation.
An accelerated, hypofractionated radiation protocol
was used in 17 cats with nasal or periocular squamous
cell carcinoma. We analyzed the DFI in this radiation
therapy protocol and whether the proliferative activity
plays a role in the success of such a treatment approach.
This radiation protocol lead to an excellent response
rate (94% complete response), which is higher than that
observed in other studies, in which between 35 and 60%
of patients showed complete response.4,7,8 The DFI with
a median of 414 days was comparable to that in the
studies of Carlisle and Gould with a DFI of 13 months
(390 days), Fidel et al8 with a DFI of 440 days
(14.6 months), or The´on et al4 with a DFI of
16.5 months (502 days). In our study, no control
population was treated with a conventional radiation
regimen, which makes statements about efficacy diffi-
cult. In comparison with results from available litera-
ture, including a variety of different radiation protocols,
ours appears to be an efficient treatment protocol. The
accelerated regimen may have been advantageous for
predominantly rapidly dividing, high-grade tumors. The
short interval between treatments likely counteracted the
rapid regrowth of the squamous cell carcinomas, which
has been described as a major factor in treatment failure
in fast-growing neoplasms.4
Most tumors in this study had a relatively high
percentage of Ki67-positive cells on immunohistochem-
istry, supporting the suspected fast growth pattern of
squamous cell carcinomas. No statistically significant
difference was found in the amount of positive staining
independent of the histologic grade or stage. In
squamous cell carcinomas in humans, the labeling index
of Ki67 has been reported to correlate with prog-
nosis.18–21 A higher labeling index of Ki67 indicates
a poorer prognosis with a higher frequency of metasta-
sis. The risk for metastasis could not be evaluated in our
study because of the low number of patients. However,
DFI was significantly shorter in cats with low Ki67
score. This finding indicates that in cats Ki67 may not
necessarily be a negative prognostic factor for metasta-
sis, but it is a positive prognostic factor for treatment
response. Nevertheless, the number of cats diagnosed
with local or distant metastasis in our study was higher
than in other studies.2,4–6,8 Whether aggressive treatment
could have influenced the metastatic rate (eg. by up-
regulating growth factors) is unknown but possible.22
In our study, a higher proportion of cats had high-
grade tumors as compared to other studies. For
example, the cats in the study of The´on et al4 consisted
of equal numbers of grade I, II, and III tumors. This
difference was unlikely due to slight difference in the
grading system used, but might truly reflect the higher
proportion of malignant tumors in our study. Grade was
Fig 2. Cat before radiation therapy, after 3 weeks, and after 3 months.
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not correlated with stage, localization of tumor, or Ki67
reactivity in the cat population of the present study.
Therefore, our findings support the conclusion of the
study of The´on et al4 study that grade is not a prognostic
factor for DFI or response in nasal and periocular
squamous cell carcinomas of cats.
Median DFI of cats treated with this radiation
regimen was 414 days, with 1- and 2-year DFIs of 66
and 40%, respectively. These numbers are comparable
to, or only slightly below, those of previous studies.4,7,8
In 3 cats, the question arises if tumor recurrence was
true recurrence or new growth of tumor because they
occurred long after initial radiation therapy (DFI5 414,
977, and 1,450 days, respectively) and showed a slow
growth pattern.
Generally, treatment was very well tolerated, with
moderate acute radiation reactions in most cats. The
reactions did not markedly differ from those observed in
previous studies, although treatment was more aggres-
sive.4,7 Most acute adverse effects were resolved by the
3rd week after radiation. Five cats were followed up for
.3 years, and no serious late effects such as bone
necrosis were detected.
Cats with high proliferative activity had a significantly
longer DFI than cats with low proliferative activity.
Direct comparison of the different studies is very
difficult because many different treatment protocols
were used. Our study shows that this accelerated,
hypofractionated radiation regimen appears particularly
suitable to eradicate fast-growing tumors, because
tumors with high Ki67 scores achieved longer tumor
control than tumors with low scores. For cats, a short
treatment time (ie, time at the hospital) may be
advantageous over conventional treatment, because
many cats become fractious toward the end of treat-
ment.4,7 Additional studies are necessary to evaluate the
influence of Ki67 on DFI with the above-mentioned
therapy protocol as compared to conventional proto-
cols. Previous studies with a conventionally fractionated
protocol4 or even prolonged treatment time7 were well
tolerated and achieved good tumor control, which
suggests that duration of treatment may have little
influence on control of feline squamous cell carcinomas.
In conclusion, we showed that an accelerated
radiation treatment protocol is effective in treating
feline squamous cell carcinomas. Examination of our
data indicates that this finding is especially true for
tumors with high proliferative activity. Assessment of
a proliferation score before therapy could be helpful in
the decision of a suitable treatment protocol.
Footnotes
aDynaray LA20, ABB/VARIAN, Switzerland
bDormicum, Midazolamum, Roche Pharma AG, Reinach, Swit-
zerland
c Propofol 1% Fresenius, Propofolum,Fresenius Kabi AG, Stans,
Switzerland
dNarketan 10, Ketaminum, Ve´toquinol AG, Bern, Switzerland
eValium, Diazepamum, Roche Pharma AG, Reinach, Switzerland
f ChemMate System
gClone MIB-1, M7240, DAKO, Zug, Switzerland
h StatView, Version 5.0.1, SAS Institute Inc, Cary, NC
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